<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="brief-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Rep</journal-id><journal-id journal-id-type="publisher-id">idr</journal-id><journal-title-group><journal-title>Infectious Disease Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7430</issn><issn pub-type="epub">2036-7449</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407644</article-id><article-id pub-id-type="pmc">PMC12101388</article-id>
<article-id pub-id-type="doi">10.3390/idr17030042</article-id><article-id pub-id-type="publisher-id">idr-17-00042</article-id><article-categories><subj-group subj-group-type="heading"><subject>Brief Report</subject></subj-group></article-categories><title-group><article-title>Humoral and Cell-Mediated Immunity Against SARS-CoV-2 in Healthcare Personnel Who Received Multiple mRNA Vaccines: A 4-Year Observational Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-7853-5721</contrib-id><name><surname>Kato</surname><given-names>Hideaki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-idr-17-00042" ref-type="aff">1</xref><xref rid="af2-idr-17-00042" ref-type="aff">2</xref><xref rid="c1-idr-17-00042" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Sano</surname><given-names>Kaori</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-idr-17-00042" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Miyakawa</surname><given-names>Kei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af3-idr-17-00042" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Kurosawa</surname><given-names>Takayuki</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="af4-idr-17-00042" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Horikawa</surname><given-names>Kazuo</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="af2-idr-17-00042" ref-type="aff">2</xref><xref rid="af5-idr-17-00042" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Kimura</surname><given-names>Yayoi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-idr-17-00042" ref-type="aff">2</xref><xref rid="af5-idr-17-00042" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name><surname>Goto</surname><given-names>Atsushi</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af2-idr-17-00042" ref-type="aff">2</xref><xref rid="af6-idr-17-00042" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name><surname>Ryo</surname><given-names>Akihide</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af7-idr-17-00042" ref-type="aff">7</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Rachiotis</surname><given-names>George</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-idr-17-00042"><label>1</label>Infection Prevention and Control Department, Yokohama City University Hospital, Yokohama 236-0004, Japan</aff><aff id="af2-idr-17-00042"><label>2</label>Emerging Infectious Diseases Research Center, Yokohama City University Hospital, Yokohama 236-0004, Japan</aff><aff id="af3-idr-17-00042"><label>3</label>Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Musashimurayama 208-0011, Japan</aff><aff id="af4-idr-17-00042"><label>4</label>Clinical Laboratory Department, Yokohama City University Hospital, Yokohama 236-0004, Japan</aff><aff id="af5-idr-17-00042"><label>5</label>Advanced Medical Research Center, Yokohama City University, Yokohama 236-0004, Japan</aff><aff id="af6-idr-17-00042"><label>6</label>Department of Public Health, Yokohama City University School of Medicine, Yokohama 236-0004, Japan</aff><aff id="af7-idr-17-00042"><label>7</label>Department of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security, Musashimurayama 208-0011, Japan</aff><author-notes><corresp id="c1-idr-17-00042"><label>*</label>Correspondence: <email>ekato@yokohama-cu.ac.jp</email>; Tel.: +81-45-787-2800</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>42</elocation-id><history><date date-type="received"><day>25</day><month>3</month><year>2025</year></date><date date-type="rev-recd"><day>23</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>24</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives:</bold> The long-term effects of multiple updated vaccinations against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have not been clarified. Humoral or cellular immunity dynamics in healthcare workers for four years were analyzed. <bold>Methods:</bold> Blood samples were collected at five time points from April 2021 to January 2024. Humoral immunity was analyzed using the 50% neutralizing titer (NT<sub>50</sub>) against the original Omicron XBB and Omicron BA.2.86 strains and cellular immunity were analyzed using the ELISpot interferon-gamma releasing assay. NT<sub>50</sub>s and the spot-forming count (SFC) of the ELISpot assay were compared in the SARS-CoV-2 Omicron XBB-, Omicron-infected, and uninfected subjects. <bold>Results</bold>: 32 healthcare workers (median age, 47 years) who received 3&#x02013;7 vaccine doses were enrolled. The NT<sub>50</sub>s against the original strain decreased after the second vaccination but were maintained after the third vaccine dose. NT<sub>50</sub>s against the Omicron XBB and BA.2.86 strains were detected before the Omicron vaccine was introduced and increased following the updated vaccination. The NT<sub>50</sub>s against the Omicron XBB and BA.2.86 strains were elevated after natural infection by the Omicron strain, albeit without differences compared with the findings in uninfected subjects. Multivariate regression analysis revealed no confounder that affected the antibody titer against the BA.2.86 strain at the fifth blood sampling. The median number of SFCs ranged from 78 to 208 after the first two doses. <bold>Conclusions</bold>: Multiple vaccinations induced the production of antibodies with divergent activity against emerging mutant strains and enhanced protective effects against the original strain. This finding supported the importance of updated vaccination.</p></abstract><kwd-group><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>humoral immunity</kwd><kwd>updated vaccine</kwd><kwd>cell-mediated immunity</kwd><kwd>interferon-gamma releasing assay</kwd><kwd>50% neutralizing titer</kwd><kwd>ELISpot</kwd><kwd>original antigenic sin</kwd><kwd>antibody divergence</kwd></kwd-group><funding-group><award-group><funding-source>Takeda Science Foundation</funding-source><award-id>90015300</award-id></award-group><funding-statement>This work was supported in part by a research grant (90015300) from the Takeda Science Foundation (A.R.).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-idr-17-00042"><title>1. Introduction</title><p>During the coronavirus disease 2019 (COVID-19) pandemic, humoral and cell-mediated immunity both protected against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection and reduced the severity of natural infection. Antibody titers declined markedly 6 months after the initial vaccination, leading to the introduction of booster vaccines [<xref rid="B1-idr-17-00042" ref-type="bibr">1</xref>]. During the Omicron variant period, three doses of the mRNA vaccine were required to provide elemental immunity against SARS-CoV-2 [<xref rid="B2-idr-17-00042" ref-type="bibr">2</xref>]. Meanwhile, the vaccine&#x02019;s effect in preventing severe disease was suggested to persist longer than its effect on antibody titers [<xref rid="B3-idr-17-00042" ref-type="bibr">3</xref>], suggesting that immune memory remains as cell-mediated immunity [<xref rid="B4-idr-17-00042" ref-type="bibr">4</xref>]. However, the longitudinal dynamics of humoral and cell-mediated immunity are not well understood. RNA viruses easily mutate, and SARS-CoV-2 evolved to spread widely [<xref rid="B5-idr-17-00042" ref-type="bibr">5</xref>,<xref rid="B6-idr-17-00042" ref-type="bibr">6</xref>]. Therefore, it is recommended that all individuals regularly receive updated vaccines [<xref rid="B7-idr-17-00042" ref-type="bibr">7</xref>]. In this background, we assessed humoral and cell-mediated immunity over 4 years in a cohort of healthcare workers who received multiple vaccinations, including subjects who were and were not infected by the SARS-CoV-2 Omicron strain. This study will provide data for clarifying the need for catch-up immunization with updated vaccines.</p></sec><sec id="sec2-idr-17-00042"><title>2. Materials and Methods</title><p>This study initially recruited 44 full-time healthcare workers at our hospital in April 2021. Ten subjects were excluded because fewer than four blood samples were obtained. Two additional subjects were excluded because they were infected with SARS-CoV-2 prior to receiving the first two doses of the vaccine. Finally, 32 participants who underwent four or five blood samplings between April 2021 and January 2024 were analyzed. As detailed in <xref rid="idr-17-00042-f001" ref-type="fig">Figure 1</xref>, blood was collected from the participants at 6 weeks (time point A) and 6 months (time point B) after the first two vaccinations in 2021, immediately after the third vaccination and the emergence of the Omicron strain in January 2022 (time point C), after receipt of the Omicron BA.4/5 bivalent vaccine and the spread of the Omicron XBB strain in summer 2023 (time point D), and after receipt of the Omicron XBB monovalent vaccine and emergence of the Omicron JN.1 strain in January&#x02013;February 2024 (time point E). Cell-mediated immunity was also assessed at time points B, C, and E.</p><p>Stored sera were brought to room temperature in February 2024 and assayed. The neutralizing titer assay was performed using an HIV-based pseudovirus bearing the SARS-CoV-2 spike [<xref rid="B8-idr-17-00042" ref-type="bibr">8</xref>]. Then, the 50% neutralizing titer (NT<sub>50</sub>) was calculated using ImageJ software version 1.54i (National Institute of Health, Bethesda, MD, USA). NT<sub>50</sub> &#x02264; a20 was considered negative. When the serum exhibited no observable neutralizing activity to interpolate NT<sub>50</sub>, it was assigned an NT<sub>50</sub> of 10. All samples were assayed in at least duplicate experiments. The original (D614G), XBB, and BA.2.86 strains were selected as targets for the NT<sub>50</sub> assay because these strains were predominant in 2023 and 2024 and exhibited strong immune escape [<xref rid="B8-idr-17-00042" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00042" ref-type="bibr">9</xref>]. BA. 2.86 was the ancestral strain of the circulating variant in 2025.</p><p>To analyze cell-mediated immunity, the IFN-&#x003b3; ELISpot assay (T-SPOT Discovery SARS-CoV-2, Oxford Immunotec Ltd., Abingdon, UK) was used. The IFN-&#x003b3; ELISpot assay was performed by stimulating a SARS-CoV-2-specific peptide pool derived from the original strain [<xref rid="B10-idr-17-00042" ref-type="bibr">10</xref>]. IFN-&#x003b3; is released by CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocytes; thus, the ELISpot assay likely measured responses from both cell types. The peptide pool for the spike protein used in the IFN-&#x003b3; ELISpot assay excluded the S2 region (C-terminal) to avoid cross-reactivity with endemic coronaviruses [<xref rid="B11-idr-17-00042" ref-type="bibr">11</xref>]. The response to emerging variants did not differ considerably between the original strain and variants of concern, such as Delta and Omicron [<xref rid="B12-idr-17-00042" ref-type="bibr">12</xref>]. Blood samples for the ELISpot assay were submitted to the SRL (H.U. Holdings, Tokyo, Japan) on the same day of sampling. T-Cell Xtend reagent (Oxford Immunotec) was also used appropriately according to the manufacturer&#x02019;s instructions. The number of spot-forming cells (SFCs) per 250,000 peripheral blood mononuclear cells (PBMCs) was calculated by subtracting the number of SFCs in the negative control panel from the number of SFCs in Spot 1 (peptide pool for spike protein). The number of SFCs was multiplied by four to express the final results per 1 &#x000d7; 10<sup>6</sup> PBMCs.</p><p>Study subjects were queried regarding their vaccination history (number of vaccinations and their dates) and their COVID-19 infection history (dates of infection). During the study period, mRNA vaccines manufactured by Pfizer (New York, NY, USA) and Moderna (Cambridge, MA, USA) were available in Japan, and receipt of either vaccine was counted as vaccination. The health status of participants was also assessed. Subjects with a history of severe immunosuppression, including organ transplantation, hematopoietic stem cell transplantation, general oral corticosteroid therapy, hemodialysis, anticancer chemotherapy, and B-cell-depleting chemotherapy, were excluded.</p><p>The history of COVID-19 was defined as a laboratory-confirmed COVID-19 diagnosis or positivity for nucleocapsid protein IgG. The infecting variant was determined as the epidemiologically circulating variant at each time, as opposed to the RNA sequence.</p><p>Continuous data were reported as the mean and 95% confidence interval (CI), median and interquartile range (IQR), or geometric mean titer (GMT). Categorical data were presented as numbers and percentages. Data were analyzed using the Mann&#x02013;Whitney U-test or Kruskal&#x02013;Wallis test to compare continuous variables between two groups or among three groups, respectively. Multivariate regression analyses using potential confounders, including age, sex, the number of mRNA vaccine doses, and the SARS-CoV-2 infection history, were performed to identify the predictors of NT<sub>50</sub>. Receiver&#x02013;operator analysis was used to predict NT50 values for distinguishing the history of SARS-CoV-2 infection. Statistical analyses were performed using Prism 10 (GraphPad Software, Boston, MA, USA). <italic toggle="yes">p</italic> &#x0003c; 0.05 was considered statistically significant. Written informed consent was obtained independently from each participant. This study was approved by the Yokohama City University Hospital ethics board (FF231100032).</p></sec><sec sec-type="results" id="sec3-idr-17-00042"><title>3. Results</title><sec id="sec3dot1-idr-17-00042"><title>3.1. Subjects&#x02019; Characteristics</title><p>The median age of the participants in April 2021 was 47 years [42&#x02013;51], and the cohort included 10 men and 22 women. The median number of mRNA vaccinations was six [5&#x02013;7]. The time between the last vaccination and each blood collection time point was as follows: time point A, 6 &#x000b1; 1 weeks; time point B, 176 days [174&#x02013;180]; time point C, 23 days [21&#x02013;28]; time point D, 25 days [18&#x02013;160]; and time point E, 84 days [61&#x02013;310]. In total, 32, 32, 31, 23, and 32 blood samples were obtained at time points A&#x02013;E, respectively. Eighteen subjects had a history of infection during the Omicron period, whereas 14 had no history of SARS-CoV-2 infection. A summary of each participant&#x02019;s vaccination and infection history, characteristics, and drawn blood samples is provided in the <xref rid="app1-idr-17-00042" ref-type="app">Supplemental Material (Figure S1)</xref>.</p></sec><sec id="sec3dot2-idr-17-00042"><title>3.2. Analysis of Humoral Immunity</title><p>The summary of the NT<sub>50</sub> against each strain at each time point is presented in <xref rid="idr-17-00042-f002" ref-type="fig">Figure 2</xref>. The GMTs of antibodies against the original strain (D614G) among the 32 subjects at time points A&#x02013;E were 551.2, 57.9, 1801, 1676, and 1612, respectively (<xref rid="idr-17-00042-f002" ref-type="fig">Figure 2</xref>A). The GMT for the D614G strain significantly decreased 6 months after the first two vaccinations (<italic toggle="yes">p</italic> &#x0003c; 0.001), but a rebound was noted after the third vaccination (no significant difference between time points C and D or between time points D and E). The GMTs of antibodies against the Omicron XBB and BA.2.86 strains were not detected at time points A and B, but they were detected at time point C, at which point the Omicron-contained vaccine had not been introduced. The GMTs of antibodies against the D614G strain were consistently higher than those against XBB.1.5 and BA.2.86 in the study subjects at time points C (1801, 22.0, and 38.9, respectively), D (1676, 100.4, and 132.7, respectively), and E (1612, 217.4, and 242.0, respectively).</p><p>At time point D, at which time the Omicron strain had emerged, subjects who had been infected with the Omicron strain exhibited higher NT<sub>50</sub>s against the XBB (GMT: 195.1 vs. 76.4, <italic toggle="yes">p</italic> = 0.053; <xref rid="idr-17-00042-f002" ref-type="fig">Figure 2</xref>B) and BA.2.86 strains (GMT: 210.5 vs. 109.7, <italic toggle="yes">p</italic> = 0.162; <xref rid="idr-17-00042-f002" ref-type="fig">Figure 2</xref>C) than those who were not infected by this strain. At time point E, at which time the Omicron XBB strain had spread, subjects infected with the Omicron or Omicron XBB strain exhibited higher NT<sub>50</sub>s against the XBB (GMT: 260.8 vs. 172.0, <italic toggle="yes">p</italic> = 0.482) and Omicron BA.2.86 strains (GMT: 288.4 vs. 193.1, <italic toggle="yes">p</italic> = 0.587) than their uninfected counterparts, although these differences were not significant.</p></sec><sec id="sec3dot3-idr-17-00042"><title>3.3. Analysis of Cell-Mediated Immunity</title><p>The median number of SFCs (per 1 &#x000d7; 10<sup>6</sup> PBMCs) at time points B, C, and E in the whole cohort were 78 [44&#x02013;149], 208 [132&#x02013;488], and 78 [45&#x02013;450], respectively. The number of SFCs was significantly higher at time point C than at time points B (<italic toggle="yes">p</italic> &#x0003c; 0.001) and E (<italic toggle="yes">p</italic> = 0.014). A comparison of SFC counts in Omicron XBB-infected, Omicron-infected, and uninfected subjects is presented in <xref rid="idr-17-00042-f003" ref-type="fig">Figure 3</xref>. The numbers of SFCs did not differ among these three groups of patients at any time point. At time point E, the median number of SFCs did not differ between subjects infected with the Omicron or Omicron XBB strain and uninfected subjects (82 vs. 78, <italic toggle="yes">p</italic> = 0.830).</p></sec><sec id="sec3dot4-idr-17-00042"><title>3.4. Factors Affecting Humoral Immunity in the Subjects Received Multiple Vaccination</title><p>Multivariate linear regression analysis was performed to investigate the factors affecting NT<sub>50</sub>s against the Omicron BA.2.86 strain. At time point E, subjects&#x02019; mean age (1.080 [95% CI = &#x02212;63.2 to 65.4]), sex (&#x02212;475.2 [95% CI = &#x02212;1556 to 605.6]), number of vaccinations (262.9 [95% CI = &#x02212;150.9 to 676.6]), and SARS-CoV-2 infection history (456.6 [95% CI = &#x02212;507.2 to 1420]). At time point E, receiver&#x02013;operator analysis of NT50 against the XBB.1.5 and BA.2.86 strains yielded an area under the curve of 0.58 [95% CI = 0.37&#x02013;0.78] (<italic toggle="yes">p</italic> = 0.47) for XBB.1.5 and 0.56 [95% CI = 0.35&#x02013;0.76] (<italic toggle="yes">p</italic> = 0.57) for BA.2.86.</p></sec></sec><sec sec-type="discussion" id="sec4-idr-17-00042"><title>4. Discussion</title><p>This study analyzed humoral and cell-mediated immunity over a 4-year study period among healthcare personnel who received multiple mRNA vaccinations against COVID-19. Antibody titers against the original strain were maintained after the third vaccination. Antibodies against emerging strains such as Omicron XBB and Omicron BA.2.86 were observed in subjects with no exposure to these strains. Meanwhile, with additional vaccination optimized to the emerging strain (e.g., Omicron BA.4/5 and Omicron XBB strains), the antibody titer against the original strain did not decline. This result revealed that the vaccination against a specific strain introduced cross-immunity against the variant strains, in line with previous basic research [<xref rid="B13-idr-17-00042" ref-type="bibr">13</xref>]. Previous studies have indicated that repeated vaccination may lead to immune imprinting, whereby a robust immune response against the original strain may compromise the efficacy of new vaccines targeting emerging variants such as the Omicron XBB strain [<xref rid="B14-idr-17-00042" ref-type="bibr">14</xref>,<xref rid="B15-idr-17-00042" ref-type="bibr">15</xref>]. In contrast, Kotaki et al. demonstrated that updated vaccines shift antibody production from the original strain toward emerging variants, resulting in enhanced humoral responses to novel variants but diminished responses to the original strain [<xref rid="B16-idr-17-00042" ref-type="bibr">16</xref>]. This suggested that memory B cells primed with the original strain can be redirected from the original strain toward emerging Omicron variants. Conversely, Alsoussi et al. reported that SARS-CoV-2 booster immunizations do not redirect B cells biased toward the original strain but instead generate robust de novo B-cell responses primarily targeting variant-specific epitopes [<xref rid="B17-idr-17-00042" ref-type="bibr">17</xref>]. Notably, our present study revealed that the Omicron-directed updated vaccine elicited humoral immune responses against newly emerged variants without attenuating immunity against the original strain. These findings suggest the concurrent operation of both B-cell redirection and responses occurring in synergistic interplay. This immunological coordination is further supported by cohort evidence demonstrating that individuals who received three vaccinations against the original strain developed diverse antibodies exhibiting cross-reactivity against both the original strain and newly emerged variants [<xref rid="B18-idr-17-00042" ref-type="bibr">18</xref>]. Our results further substantiate the conclusion that multiple doses of Omicron-directed vaccines establish broad and effective humoral immunity against both emerging variants and the original strain through these dual mechanisms [<xref rid="B19-idr-17-00042" ref-type="bibr">19</xref>].</p><p>In the Omicron era, the receipt of three vaccine doses provided greater protection against SARS-CoV-2 infection than the receipt of two vaccine doses [<xref rid="B20-idr-17-00042" ref-type="bibr">20</xref>]. In our previous report, additional vaccine doses helped maintain or strengthen the antibody titers against circulating variant strains among subjects vaccinated 4&#x02013;6 times [<xref rid="B21-idr-17-00042" ref-type="bibr">21</xref>]. We also reported that subjects with prior infection had approximately 2-fold higher spike-specific IgG titers than uninfected subjects [<xref rid="B21-idr-17-00042" ref-type="bibr">21</xref>]. The combination of natural infection and vaccination provided hybrid immunity [<xref rid="B22-idr-17-00042" ref-type="bibr">22</xref>]. However, among subjects who underwent multiple vaccinations (3&#x02013;7 doses) with or without SARS-CoV-2 infection, the prior infection had no apparent effect on NT<sub>50</sub>s. In this study, the antibody titers of subjects who underwent multiple vaccinations appeared to converge, and the effect of natural infection on immunity became more difficult to recognize. These data were observed in study participants but not confirmed at the cellular level. A cell-level analysis of circulating peripheral mononuclear cells will be warranted to further characterize the specific B cell response to a particular endemic variant [<xref rid="B23-idr-17-00042" ref-type="bibr">23</xref>].</p><p>Newly emerged mutant strains, such as strain JN.1, a descendant of BA.2.86, have been reported to have high immune escape potential and a high propensity to cause reinfection in previously infected individuals [<xref rid="B24-idr-17-00042" ref-type="bibr">24</xref>]. In this study, the NT<sub>50</sub>s against XBB.1.5 and BA.2.86 were significantly lower than those against the original strain (D614G), supporting the evidence of the immune escape of the emerging strains. An antibody-dependent cell-mediated cytotoxicity assay using subjects&#x02019; sera may be a promising approach for future convalescent plasma therapy.</p><p>We evaluated cell-mediated immunity using the ELISpot analysis at three time points. The efficacy of the first two vaccinations in preventing infection declined after 6 months, but the efficacy in preventing severe disease was maintained longer [<xref rid="B3-idr-17-00042" ref-type="bibr">3</xref>]. Although the effect of vaccination on the peak SFC count was not clarified, the recent &#x0201c;human challenge study&#x0201d; revealed that after SARS-CoV-2 infection, the numbers of spike S1- and S2-specific SFCs (per 1 &#x000d7; 10<sup>6</sup> PMBCs) increased from 141 to 409 [IQR 251&#x02013;804] and from 211 to 467 [IQR 159&#x02013;783], respectively, compared with those before the infection [<xref rid="B25-idr-17-00042" ref-type="bibr">25</xref>]. It has been reported that cell-mediated immunity also gradually declines after 6 months [<xref rid="B26-idr-17-00042" ref-type="bibr">26</xref>]. In this study, it was unclear why the number of SFCs was higher at time point D than at time points B and E. We consider that the initial two doses possibly provided a certain level of cellular immunity that was subsequently maintained [<xref rid="B27-idr-17-00042" ref-type="bibr">27</xref>]. T-cell activity induced by the vaccine also provided an immune response against the variants of concern [<xref rid="B28-idr-17-00042" ref-type="bibr">28</xref>].</p><p>The study had several limitations. The cohort was small, with approximately 10 subjects each in the Omicron XBB-infected, Omicron-infected, and uninfected groups. Our study also had potential selection bias, as the study participants were likely more sensitive to infections and more likely to undergo vaccination. This study included only immunocompetent individuals; therefore, our data may be inapplicable to immunosuppressed patients, such as those with cancer or organ transplants [<xref rid="B29-idr-17-00042" ref-type="bibr">29</xref>,<xref rid="B30-idr-17-00042" ref-type="bibr">30</xref>]. Ideally, the interval between blood sampling and the last vaccination should be standardized to more accurately assess the immune response at each time point. Herein, we used the IFN-&#x003b3; ELISpot assay, which measures CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses. Analysis of CD4+ or CD8+ memory T-cells activity will be warranted to evaluate the role of T-cell in long-term immunity.</p><p>In this study, we focused on subjects infected with SARS-CoV-2. However, many RNA viruses mutate easily. Thus, vaccine development for RNA viruses is a key issue. Our study indicated that multiple vaccinations induced the production of antibodies with divergent activity against emerging mutant strains and enhanced protection the original strain. The difference in humoral immunity between the subjects with or without infection history was eliminated among subjects who underwent multiple vaccinations.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-idr-17-00042"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/idr17030042/s1">https://www.mdpi.com/article/10.3390/idr17030042/s1</uri>, Figure S1: The characteristics of the subjects in this study, such as the age at the time of recruitment, sex, doses of mRNA COVID-19 vaccines received, and the timing of blood sampling, vaccination, and SARS-CoV-2 infection, are provided in this section.</p><supplementary-material id="idr-17-00042-s001" position="float" content-type="local-data"><media xlink:href="idr-17-00042-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, H.K.; Data curation, H.K. and K.H.; Formal analysis, K.S., K.M., T.K., K.H., and Y.K.; Methodology, H.K. and A.R.; Supervision, K.S., K.M., Y.K., A.G., and A.R.; Writing&#x02014;original draft, H.K.; Writing&#x02014;review and editing, H.K. and A.R. All authors will be updated at each stage of manuscript processing, including submission, revision, and revision reminder, via emails from our system or the assigned assistant editor. All authors meet the ICMJE authorship criteria. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was approved by the Yokohama City University Hospital ethics board (FF231100032).</p></notes><notes><title>Informed Consent Statement</title><p>Written informed consent was obtained independently from each participant.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data presented in this study are available on request from the corresponding author due to the future analysis of the data.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><glossary><title>Abbreviations</title><p>The following abbreviations are used in this manuscript:
<array><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">CI</td><td align="left" valign="middle" rowspan="1" colspan="1">Confidence interval</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GMT</td><td align="left" valign="middle" rowspan="1" colspan="1">Geometric mean titer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PBMC</td><td align="left" valign="middle" rowspan="1" colspan="1">Peripheral blood mononuclear cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">SFC</td><td align="left" valign="middle" rowspan="1" colspan="1">Spot-forming cells</td></tr></tbody></array></p></glossary><ref-list><title>References</title><ref id="B1-idr-17-00042"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Levin</surname><given-names>E.G.</given-names></name>
<name><surname>Lustig</surname><given-names>Y.</given-names></name>
<name><surname>Cohen</surname><given-names>C.</given-names></name>
<name><surname>Fluss</surname><given-names>R.</given-names></name>
<name><surname>Indenbaum</surname><given-names>V.</given-names></name>
<name><surname>Amit</surname><given-names>S.</given-names></name>
<name><surname>Doolman</surname><given-names>R.</given-names></name>
<name><surname>Regev-Yochay</surname><given-names>G.</given-names></name>
</person-group><article-title>Waning immune humoral response to BNT162b2 COVID-19 vaccine over 6 months</article-title><source>N. Engl. J. Med.</source><year>2021</year><volume>385</volume><fpage>e84</fpage><pub-id pub-id-type="doi">10.1056/NEJMoa2114583</pub-id><pub-id pub-id-type="pmid">34614326</pub-id>
</element-citation></ref><ref id="B2-idr-17-00042"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>X.</given-names></name>
</person-group><article-title>Boosting immunity to omicron</article-title><source>Nat. Med.</source><year>2022</year><volume>28</volume><fpage>445</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1038/s41591-022-01727-0</pub-id><pub-id pub-id-type="pmid">35210597</pub-id>
</element-citation></ref><ref id="B3-idr-17-00042"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tartof</surname><given-names>S.Y.</given-names></name>
<name><surname>Slezak</surname><given-names>J.M.</given-names></name>
<name><surname>Fischer</surname><given-names>H.</given-names></name>
<name><surname>Hong</surname><given-names>V.</given-names></name>
<name><surname>Ackerson</surname><given-names>B.K.</given-names></name>
<name><surname>Ranasinghe</surname><given-names>O.N.</given-names></name>
<name><surname>Frankland</surname><given-names>T.B.</given-names></name>
<name><surname>Ogun</surname><given-names>O.A.</given-names></name>
<name><surname>Zamparo</surname><given-names>J.M.</given-names></name>
<name><surname>Gray</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: A retrospective cohort study</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>1407</fpage><lpage>1416</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02183-8</pub-id><pub-id pub-id-type="pmid">34619098</pub-id>
</element-citation></ref><ref id="B4-idr-17-00042"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kato</surname><given-names>H.</given-names></name>
<name><surname>Miyakawa</surname><given-names>K.</given-names></name>
<name><surname>Ohtake</surname><given-names>N.</given-names></name>
<name><surname>Yamaoka</surname><given-names>Y.</given-names></name>
<name><surname>Yajima</surname><given-names>S.</given-names></name>
<name><surname>Yamazaki</surname><given-names>E.</given-names></name>
<name><surname>Shimada</surname><given-names>T.</given-names></name>
<name><surname>Goto</surname><given-names>A.</given-names></name>
<name><surname>Nakajima</surname><given-names>H.</given-names></name>
<name><surname>Ryo</surname><given-names>A.</given-names></name>
</person-group><article-title>Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination</article-title><source>Vaccine</source><year>2022</year><volume>40</volume><fpage>2652</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2022.03.057</pub-id><pub-id pub-id-type="pmid">35370020</pub-id>
</element-citation></ref><ref id="B5-idr-17-00042"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Furi&#x000f3;</surname><given-names>V.</given-names></name>
<name><surname>Moya</surname><given-names>A.</given-names></name>
<name><surname>Sanju&#x000e1;n</surname><given-names>R.</given-names></name>
</person-group><article-title>The cost of replication fidelity in an RNA virus</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2005</year><volume>102</volume><fpage>10233</fpage><lpage>10237</lpage><pub-id pub-id-type="doi">10.1073/pnas.0501062102</pub-id><pub-id pub-id-type="pmid">16006529</pub-id>
</element-citation></ref><ref id="B6-idr-17-00042"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Carabelli</surname><given-names>A.M.</given-names></name>
<name><surname>Peacock</surname><given-names>T.P.</given-names></name>
<name><surname>Thorne</surname><given-names>L.G.</given-names></name>
<name><surname>Harvey</surname><given-names>W.T.</given-names></name>
<name><surname>Hughes</surname><given-names>J.</given-names></name>
<name><surname>Peacock</surname><given-names>S.J.</given-names></name>
<name><surname>Barclay</surname><given-names>W.S.</given-names></name>
<name><surname>de Silva</surname><given-names>T.I.</given-names></name>
<name><surname>Towers</surname><given-names>G.J.</given-names></name>
<name><surname>Robertson</surname><given-names>D.L.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 variant biology: Immune escape, transmission and fitness</article-title><source>Nat. Rev. Microbiol.</source><year>2023</year><volume>21</volume><fpage>162</fpage><lpage>177</lpage><pub-id pub-id-type="doi">10.1038/s41579-022-00841-7</pub-id><pub-id pub-id-type="pmid">36653446</pub-id>
</element-citation></ref><ref id="B7-idr-17-00042"><label>7.</label><element-citation publication-type="gov"><person-group person-group-type="author">
<collab>Centers for Disease Control and Prevention</collab>
</person-group><article-title>Staying Up to Date with COVID-19 Vaccines</article-title><comment>Available online: <ext-link xlink:href="https://www.cdc.gov/covid/vaccines/stay-up-to-date.html" ext-link-type="uri">https://www.cdc.gov/covid/vaccines/stay-up-to-date.html</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2025-03-15">(accessed on 15 March 2025)</date-in-citation></element-citation></ref><ref id="B8-idr-17-00042"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>T.</given-names></name>
<name><surname>Irie</surname><given-names>T.</given-names></name>
<name><surname>Deguchi</surname><given-names>S.</given-names></name>
<name><surname>Yajima</surname><given-names>H.</given-names></name>
<name><surname>Tsuda</surname><given-names>M.</given-names></name>
<name><surname>Nasser</surname><given-names>H.</given-names></name>
<name><surname>Mizuma</surname><given-names>K.</given-names></name>
<name><surname>Plianchaisuk</surname><given-names>A.</given-names></name>
<name><surname>Suzuki</surname><given-names>S.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Virological characteristics of the SARS-CoV-2 omicron XBB.1.5 variant</article-title><source>Nat. Commun.</source><year>2024</year><volume>15</volume><fpage>1176</fpage><pub-id pub-id-type="doi">10.1038/s41467-024-45274-3</pub-id><pub-id pub-id-type="pmid">38332154</pub-id>
</element-citation></ref><ref id="B9-idr-17-00042"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tamura</surname><given-names>T.</given-names></name>
<name><surname>Mizuma</surname><given-names>K.</given-names></name>
<name><surname>Nasser</surname><given-names>H.</given-names></name>
<name><surname>Deguchi</surname><given-names>S.</given-names></name>
<name><surname>Padilla-Blanco</surname><given-names>M.</given-names></name>
<name><surname>Oda</surname><given-names>Y.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<name><surname>Tolentino</surname><given-names>J.E.M.</given-names></name>
<name><surname>Tsujino</surname><given-names>S.</given-names></name>
<name><surname>Suzuki</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>Virological characteristics of the SARS-CoV-2 BA.2.86 variant</article-title><source>Cell Host Microbe</source><year>2024</year><volume>32</volume><fpage>170</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2024.01.001</pub-id><pub-id pub-id-type="pmid">38280382</pub-id>
</element-citation></ref><ref id="B10-idr-17-00042"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kruse</surname><given-names>M.</given-names></name>
<name><surname>Dark</surname><given-names>C.</given-names></name>
<name><surname>Aspden</surname><given-names>M.</given-names></name>
<name><surname>Cochrane</surname><given-names>D.</given-names></name>
<name><surname>Competiello</surname><given-names>R.</given-names></name>
<name><surname>Peltz</surname><given-names>M.</given-names></name>
<name><surname>Torres</surname><given-names>L.</given-names></name>
<name><surname>Wrighton-Smith</surname><given-names>P.</given-names></name>
<name><surname>Dudek</surname><given-names>M.</given-names></name>
</person-group><article-title>Performance of the T-SPOT<sup>&#x000ae;</sup>. COVID test for detecting SARS-CoV-2-responsive T cells</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>113</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.09.073</pub-id><pub-id pub-id-type="pmid">34601143</pub-id>
</element-citation></ref><ref id="B11-idr-17-00042"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Braun</surname><given-names>J.</given-names></name>
<name><surname>Loyal</surname><given-names>L.</given-names></name>
<name><surname>Frentsch</surname><given-names>M.</given-names></name>
<name><surname>Wendisch</surname><given-names>D.</given-names></name>
<name><surname>Georg</surname><given-names>P.</given-names></name>
<name><surname>Kurth</surname><given-names>F.</given-names></name>
<name><surname>Hippenstiel</surname><given-names>S.</given-names></name>
<name><surname>Dingeldey</surname><given-names>M.</given-names></name>
<name><surname>Kruse</surname><given-names>B.</given-names></name>
<name><surname>Fauchere</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19</article-title><source>Nature</source><year>2020</year><volume>587</volume><fpage>270</fpage><lpage>274</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2598-9</pub-id><pub-id pub-id-type="pmid">32726801</pub-id>
</element-citation></ref><ref id="B12-idr-17-00042"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Faas</surname><given-names>M.R.</given-names></name>
<name><surname>Mak</surname><given-names>W.A.</given-names></name>
<name><surname>Markus</surname><given-names>H.Y.</given-names></name>
<name><surname>van der Zwan</surname><given-names>E.M.</given-names></name>
<name><surname>van der Vliet</surname><given-names>M.</given-names></name>
<name><surname>Koeleman</surname><given-names>J.G.M.</given-names></name>
<name><surname>Ong</surname><given-names>D.S.Y.</given-names></name>
</person-group><article-title>Dynamics of antibody and T cell immunity against SARS-CoV-2 variants of concern and the impact of booster vaccinations in previously infected and infection-na&#x000ef;ve individuals</article-title><source>Vaccines</source><year>2022</year><volume>10</volume><elocation-id>2132</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines10122132</pub-id><pub-id pub-id-type="pmid">36560542</pub-id>
</element-citation></ref><ref id="B13-idr-17-00042"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aoki</surname><given-names>H.</given-names></name>
<name><surname>Kitabatake</surname><given-names>M.</given-names></name>
<name><surname>Abe</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>P.</given-names></name>
<name><surname>Tsunoda</surname><given-names>M.</given-names></name>
<name><surname>Shichino</surname><given-names>S.</given-names></name>
<name><surname>Hara</surname><given-names>A.</given-names></name>
<name><surname>Ouji-Sageshima</surname><given-names>N.</given-names></name>
<name><surname>Motozono</surname><given-names>C.</given-names></name>
<name><surname>Ito</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>CD8<sup>+</sup> T cell memory induced by successive SARS-CoV-2 mRNA vaccinations is characterized by shifts in clonal dominance</article-title><source>Cell Rep.</source><year>2024</year><volume>43</volume><fpage>113887</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2024.113887</pub-id><pub-id pub-id-type="pmid">38458195</pub-id>
</element-citation></ref><ref id="B14-idr-17-00042"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tortorici</surname><given-names>M.A.</given-names></name>
<name><surname>Addetia</surname><given-names>A.</given-names></name>
<name><surname>Seo</surname><given-names>A.J.</given-names></name>
<name><surname>Brown</surname><given-names>J.</given-names></name>
<name><surname>Sprouse</surname><given-names>K.</given-names></name>
<name><surname>Logue</surname><given-names>J.</given-names></name>
<name><surname>Clark</surname><given-names>E.</given-names></name>
<name><surname>Franko</surname><given-names>N.</given-names></name>
<name><surname>Chu</surname><given-names>H.</given-names></name>
<name><surname>Veesler</surname><given-names>D.</given-names></name>
</person-group><article-title>Persistent immune imprinting occurs after vaccination with the COVID-19 XBB.1.5 mRNA booster in humans</article-title><source>Immunity</source><year>2024</year><volume>57</volume><fpage>904</fpage><lpage>911</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2024.02.016</pub-id><pub-id pub-id-type="pmid">38490197</pub-id>
</element-citation></ref><ref id="B15-idr-17-00042"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Addetia</surname><given-names>A.</given-names></name>
<name><surname>Piccoli</surname><given-names>L.</given-names></name>
<name><surname>Case</surname><given-names>J.B.</given-names></name>
<name><surname>Park</surname><given-names>Y.</given-names></name>
<name><surname>Beltramello</surname><given-names>M.</given-names></name>
<name><surname>Guarino</surname><given-names>B.</given-names></name>
<name><surname>Clark</surname><given-names>E.</given-names></name>
<name><surname>Franko</surname><given-names>N.</given-names></name>
<name><surname>Chu</surname><given-names>H.</given-names></name>
<name><surname>Veesler</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Neutralization, effector function and immune imprinting of omicron variants</article-title><source>Nature</source><year>2023</year><volume>621</volume><fpage>592</fpage><lpage>601</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06487-6</pub-id><pub-id pub-id-type="pmid">37648855</pub-id>
</element-citation></ref><ref id="B16-idr-17-00042"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kotaki</surname><given-names>R.</given-names></name>
<name><surname>Moriyama</surname><given-names>S.</given-names></name>
<name><surname>Oishi</surname><given-names>S.</given-names></name>
<name><surname>Onodera</surname><given-names>T.</given-names></name>
<name><surname>Adachi</surname><given-names>Y.</given-names></name>
<name><surname>Sasaki</surname><given-names>E.</given-names></name>
<name><surname>Ishino</surname><given-names>K.</given-names></name>
<name><surname>Morikawa</surname><given-names>M.</given-names></name>
<name><surname>Takei</surname><given-names>H.</given-names></name>
<name><surname>Takahashi</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Repeated omicron exposures redirect SARS-CoV-2-specific memory B cell evolution toward the latest variants</article-title><source>Sci. Transl. Med.</source><year>2024</year><volume>16</volume><fpage>eadp9927</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.adp9927</pub-id><pub-id pub-id-type="pmid">39167666</pub-id>
</element-citation></ref><ref id="B17-idr-17-00042"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alsoussi</surname><given-names>W.B.</given-names></name>
<name><surname>Malladi</surname><given-names>S.K.</given-names></name>
<name><surname>Zhou</surname><given-names>J.Q.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Ying</surname><given-names>B.</given-names></name>
<name><surname>Kim</surname><given-names>W.</given-names></name>
<name><surname>Schmitz</surname><given-names>A.J.</given-names></name>
<name><surname>Lei</surname><given-names>T.</given-names></name>
<name><surname>Horvath</surname><given-names>S.C.</given-names></name>
<name><surname>Sturtz</surname><given-names>A.J.</given-names></name>
<etal/>
</person-group><article-title>SARS-CoV-2 omicron boosting induces de novo B cell response in humans</article-title><source>Nature</source><year>2023</year><volume>617</volume><fpage>592</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06025-4</pub-id><pub-id pub-id-type="pmid">37011668</pub-id>
</element-citation></ref><ref id="B18-idr-17-00042"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Inoue</surname><given-names>T.</given-names></name>
<name><surname>Shinnakasu</surname><given-names>R.</given-names></name>
<name><surname>Kawai</surname><given-names>C.</given-names></name>
<name><surname>Yamamoto</surname><given-names>H.</given-names></name>
<name><surname>Sakakibara</surname><given-names>S.</given-names></name>
<name><surname>Ono</surname><given-names>C.</given-names></name>
<name><surname>Itoh</surname><given-names>Y.</given-names></name>
<name><surname>Terooatea</surname><given-names>T.</given-names></name>
<name><surname>Yamashita</surname><given-names>K.</given-names></name>
<name><surname>Okamoto</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Antibody feedback contributes to facilitating the development of omicron-reactive memory B cells in SARS-CoV-2 mRNA vaccinees</article-title><source>J. Exp. Med.</source><year>2023</year><volume>220</volume><fpage>e20221786</fpage><pub-id pub-id-type="doi">10.1084/jem.20221786</pub-id><pub-id pub-id-type="pmid">36512034</pub-id>
</element-citation></ref><ref id="B19-idr-17-00042"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yisimayi</surname><given-names>A.</given-names></name>
<name><surname>Song</surname><given-names>W.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Jian</surname><given-names>F.</given-names></name>
<name><surname>Yu</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Xu</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>S.</given-names></name>
<name><surname>Niu</surname><given-names>X.</given-names></name>
<name><surname>Xiao</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>Repeated omicron exposures override ancestral SARS-CoV-2 immune imprinting</article-title><source>Nature</source><year>2024</year><volume>625</volume><fpage>148</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1038/s41586-023-06753-7</pub-id><pub-id pub-id-type="pmid">37993710</pub-id>
</element-citation></ref><ref id="B20-idr-17-00042"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Arashiro</surname><given-names>T.</given-names></name>
<name><surname>Arima</surname><given-names>Y.</given-names></name>
<name><surname>Muraoka</surname><given-names>H.</given-names></name>
<name><surname>Sato</surname><given-names>A.</given-names></name>
<name><surname>Oba</surname><given-names>K.</given-names></name>
<name><surname>Uehara</surname><given-names>Y.</given-names></name>
<name><surname>Arioka</surname><given-names>H.</given-names></name>
<name><surname>Yanai</surname><given-names>H.</given-names></name>
<name><surname>Kuramochi</surname><given-names>J.</given-names></name>
<name><surname>Ihara</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Coronavirus disease 19 (COVID-19) vaccine effectiveness against symptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during delta-dominant and omicron-dominant periods in japan: A multicenter prospective case-control study</article-title><source>Clin. Infect. Dis.</source><year>2023</year><volume>76</volume><fpage>e108</fpage><lpage>e115</lpage><pub-id pub-id-type="doi">10.1093/cid/ciac635</pub-id><pub-id pub-id-type="pmid">35918782</pub-id>
</element-citation></ref><ref id="B21-idr-17-00042"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kato</surname><given-names>H.</given-names></name>
<name><surname>Kurosawa</surname><given-names>T.</given-names></name>
<name><surname>Horikawa</surname><given-names>K.</given-names></name>
<name><surname>Kimura</surname><given-names>Y.</given-names></name>
<name><surname>Miyakawa</surname><given-names>K.</given-names></name>
<name><surname>Ryo</surname><given-names>A.</given-names></name>
<name><surname>Goto</surname><given-names>A.</given-names></name>
</person-group><article-title>Humoral response against spike protein enhanced by fifth and sixth COVID-19 mRNA vaccine in the uninfected and infected subjects</article-title><source>Hum. Vaccin. Immunother.</source><year>2023</year><volume>19</volume><fpage>2278376</fpage><pub-id pub-id-type="doi">10.1080/21645515.2023.2278376</pub-id><pub-id pub-id-type="pmid">37969091</pub-id>
</element-citation></ref><ref id="B22-idr-17-00042"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bobrovitz</surname><given-names>N.</given-names></name>
<name><surname>Ware</surname><given-names>H.</given-names></name>
<name><surname>Ma</surname><given-names>X.</given-names></name>
<name><surname>Li</surname><given-names>Z.</given-names></name>
<name><surname>Hosseini</surname><given-names>R.</given-names></name>
<name><surname>Cao</surname><given-names>C.</given-names></name>
<name><surname>Selemon</surname><given-names>A.</given-names></name>
<name><surname>Whelan</surname><given-names>M.</given-names></name>
<name><surname>Premji</surname><given-names>Z.</given-names></name>
<name><surname>Issa</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: A systematic review and meta-regression</article-title><source>Lancet Infect. Dis.</source><year>2023</year><volume>23</volume><fpage>556</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00801-5</pub-id><pub-id pub-id-type="pmid">36681084</pub-id>
</element-citation></ref><ref id="B23-idr-17-00042"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moody</surname><given-names>M.A.</given-names></name>
<name><surname>Haynes</surname><given-names>B.F.</given-names></name>
</person-group><article-title>Antigen-specific B cell detection reagents: Use and quality control</article-title><source>Cytom. Part A J. Int. Soc. Anal. Cytol.</source><year>2008</year><volume>73</volume><fpage>1086</fpage><lpage>1092</lpage><pub-id pub-id-type="doi">10.1002/cyto.a.20599</pub-id><pub-id pub-id-type="pmid">18613115</pub-id>
</element-citation></ref><ref id="B24-idr-17-00042"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kaku</surname><given-names>Y.</given-names></name>
<name><surname>Okumura</surname><given-names>K.</given-names></name>
<name><surname>Padilla-Blanco</surname><given-names>M.</given-names></name>
<name><surname>Kosugi</surname><given-names>Y.</given-names></name>
<name><surname>Uriu</surname><given-names>K.</given-names></name>
<name><surname>Hinay</surname><given-names>A.A.J.</given-names></name>
<name><surname>Chen</surname><given-names>L.</given-names></name>
<name><surname>Plianchaisuk</surname><given-names>A.</given-names></name>
<name><surname>Kobiyama</surname><given-names>K.</given-names></name>
<name><surname>Ishii</surname><given-names>K.J.</given-names></name>
<etal/>
</person-group><article-title>Virological characteristics of the SARS-CoV-2 JN.1 variant</article-title><source>Lancet Infect. Dis.</source><year>2024</year><volume>24</volume><fpage>e82</fpage><pub-id pub-id-type="doi">10.1016/S1473-3099(23)00813-7</pub-id><pub-id pub-id-type="pmid">38184005</pub-id>
</element-citation></ref><ref id="B25-idr-17-00042"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jackson</surname><given-names>S.</given-names></name>
<name><surname>Marshall</surname><given-names>J.L.</given-names></name>
<name><surname>Mawer</surname><given-names>A.</given-names></name>
<name><surname>Lopez-Ramon</surname><given-names>R.</given-names></name>
<name><surname>Harris</surname><given-names>S.A.</given-names></name>
<name><surname>Satti</surname><given-names>I.</given-names></name>
<name><surname>Hughes</surname><given-names>E.</given-names></name>
<name><surname>Preston-Jones</surname><given-names>H.</given-names></name>
<name><surname>Puig</surname><given-names>I.C.</given-names></name>
<name><surname>Longet</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: A single-centre, open-label, phase 1 controlled human infection study</article-title><source>Lancet Microbe</source><year>2024</year><volume>5</volume><fpage>655</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1016/S2666-5247(24)00025-9</pub-id><pub-id pub-id-type="pmid">38703782</pub-id>
</element-citation></ref><ref id="B26-idr-17-00042"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishii</surname><given-names>T.</given-names></name>
<name><surname>Hamada</surname><given-names>K.</given-names></name>
<name><surname>Jubishi</surname><given-names>D.</given-names></name>
<name><surname>Hashimoto</surname><given-names>H.</given-names></name>
<name><surname>Okamoto</surname><given-names>K.</given-names></name>
<name><surname>Hisasue</surname><given-names>N.</given-names></name>
<name><surname>Sunohara</surname><given-names>M.</given-names></name>
<name><surname>Saito</surname><given-names>M.</given-names></name>
<name><surname>Shinohara</surname><given-names>T.</given-names></name>
<name><surname>Yamashita</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>Waning cellular immune responses and predictive factors in maintaining cellular immunity against SARS-CoV-2 six months after BNT162b2 mRNA vaccination</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>9607</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-36397-6</pub-id><pub-id pub-id-type="pmid">37311763</pub-id>
</element-citation></ref><ref id="B27-idr-17-00042"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Juhl</surname><given-names>A.K.</given-names></name>
<name><surname>Loks&#x000f8; Dietz</surname><given-names>L.</given-names></name>
<name><surname>Schmeltz S&#x000f8;gaard</surname><given-names>O.</given-names></name>
<name><surname>Reekie</surname><given-names>J.</given-names></name>
<name><surname>Nielsen</surname><given-names>H.</given-names></name>
<name><surname>Johansen</surname><given-names>S.</given-names></name>
<name><surname>Benfield</surname><given-names>T.</given-names></name>
<name><surname>Wiese</surname><given-names>L.</given-names></name>
<name><surname>St&#x000e6;rke</surname><given-names>N.B.</given-names></name>
<name><surname>Jensen</surname><given-names>T.&#x000d8;.</given-names></name>
<etal/>
</person-group><article-title>Longitudinal evaluation of SARS-CoV-2 T cell immunity over 2 years following vaccination and infection</article-title><source>J. Infect. Dis.</source><year>2024</year><volume>230</volume><fpage>e605</fpage><lpage>e615</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiae215</pub-id><pub-id pub-id-type="pmid">38687181</pub-id>
</element-citation></ref><ref id="B28-idr-17-00042"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keeton</surname><given-names>R.</given-names></name>
<name><surname>Tincho</surname><given-names>M.B.</given-names></name>
<name><surname>Ngomti</surname><given-names>A.</given-names></name>
<name><surname>Baguma</surname><given-names>R.</given-names></name>
<name><surname>Benede</surname><given-names>N.</given-names></name>
<name><surname>Suzuki</surname><given-names>A.</given-names></name>
<name><surname>Khan</surname><given-names>K.</given-names></name>
<name><surname>Cele</surname><given-names>S.</given-names></name>
<name><surname>Bernstein</surname><given-names>M.</given-names></name>
<name><surname>Karim</surname><given-names>F.</given-names></name>
<etal/>
</person-group><article-title>T cell responses to SARS-CoV-2 spike cross-recognize omicron</article-title><source>Nature</source><year>2022</year><volume>603</volume><fpage>488</fpage><lpage>492</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04460-3</pub-id><pub-id pub-id-type="pmid">35102311</pub-id>
</element-citation></ref><ref id="B29-idr-17-00042"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Peeters</surname><given-names>M.</given-names></name>
<name><surname>Verbruggen</surname><given-names>L.</given-names></name>
<name><surname>Teuwen</surname><given-names>L.</given-names></name>
<name><surname>Vanhoutte</surname><given-names>G.</given-names></name>
<name><surname>Vande Kerckhove</surname><given-names>S.</given-names></name>
<name><surname>Peeters</surname><given-names>B.</given-names></name>
<name><surname>Raats</surname><given-names>S.</given-names></name>
<name><surname>Van der Massen</surname><given-names>I.</given-names></name>
<name><surname>De Keersmaecker</surname><given-names>S.</given-names></name>
<name><surname>Debie</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment</article-title><source>ESMO Open.</source><year>2021</year><volume>6</volume><fpage>100274</fpage><pub-id pub-id-type="doi">10.1016/j.esmoop.2021.100274</pub-id><pub-id pub-id-type="pmid">34597941</pub-id>
</element-citation></ref><ref id="B30-idr-17-00042"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Grupper</surname><given-names>A.</given-names></name>
<name><surname>Rabinowich</surname><given-names>L.</given-names></name>
<name><surname>Schwartz</surname><given-names>D.</given-names></name>
<name><surname>Schwartz</surname><given-names>I.F.</given-names></name>
<name><surname>Ben-Yehoyada</surname><given-names>M.</given-names></name>
<name><surname>Shashar</surname><given-names>M.</given-names></name>
<name><surname>Katchman</surname><given-names>E.</given-names></name>
<name><surname>Halperin</surname><given-names>T.</given-names></name>
<name><surname>Turner</surname><given-names>D.</given-names></name>
<name><surname>Goykhman</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus</article-title><source>Am. J. Transpl.</source><year>2021</year><volume>21</volume><fpage>2719</fpage><lpage>2726</lpage><pub-id pub-id-type="doi">10.1111/ajt.16615</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="idr-17-00042-f001"><label>Figure 1</label><caption><p>Schematic of this study.</p></caption><graphic xlink:href="idr-17-00042-g001" position="float"/></fig><fig position="float" id="idr-17-00042-f002"><label>Figure 2</label><caption><p>Neutralizing antibody titer (NT<sub>50</sub>) (<bold>A</bold>) against the original strain (D614G), (<bold>B</bold>) XBB.1.5 strain, and (<bold>C</bold>) BA.2.86 strain. The box-and-whisker plot presents the median, interquartile range, minimum, and maximum at time points A&#x02013;E. Time points A and B were before the Omicron strain had emerged. At time point C, all subjects were uninfected. At time point D, nine subjects were infected by the Omicron strain. At time point E, an additional nine subjects were infected by the Omicron XBB strain. No subjects were infected twice.</p></caption><graphic xlink:href="idr-17-00042-g002" position="float"/></fig><fig position="float" id="idr-17-00042-f003"><label>Figure 3</label><caption><p>Specific lymphocyte counts as the number of spot-forming cells (SFCs) as determined by the ELISpot SARS-CoV-2 assay at time points B, C, and E. Each dot and bar represented an individual SFC count and the median.</p></caption><graphic xlink:href="idr-17-00042-g003" position="float"/></fig></floats-group></article>